Based on our model, we demonstrate that drug resistant cancer cells develop an increased malignant phenotype, in part due to enhanced adhesion and transendothelial penetration, accompanied by a significant down-regulation of the adhesion receptor NCAM. This evidence concerns the gene NCAM1 and cancer.